For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Sterling Drug Inc.

Calculating rank

USPTO Granted Patents = 692

CIPO Patents = 1

Trademarks = 39

Forward Citations = 9,804

Loading Chart...

Loading Chart...

286 inventors (with patents filed for the assignee):

George Y Lesher (107 out of 108 patents)

Baldev Singh (52 out of 62 patents)

Malcolm R Bell (47 out of 60 patents)

4. Guy D Diana (46 out of 73 patents)

5. Nathan N Crounse (43 out of 49 patents)

6. Paul J Schmidt (41 out of 78 patents)

7. Denis M Bailey (38 out of 38 patents)

8. Chester J Opalka, Jr (28 out of 28 patents)

9. William M Hung (25 out of 73 patents)

10. Heinz Eggensperger (19 out of 29 patents)

11. Donald F Page (18 out of 19 patents)

12. Joseph C Collins (17 out of 19 patents)

13. William F Michne (16 out of 23 patents)

14. Philip M Carabateas (15 out of 17 patents)

15. Sol J Daum (15 out of 25 patents)

Core Competencies:

Nuclease Resistant Compounds

Oral Pharmaceutical Gel

Antiviral Agents

Sustained-Release Formulations

Antiarrhythmic Agents

Immunomodulating Compounds

Drug Nanoparticles

Anticoagulant Compositions

Disinfectant Formulations

Oxadiazolyl Compounds

Surface Modified Nanoparticles

Carpet Cleaning Composition

692 patents: Sort by Forward Citations

1. 5567810 - Nuclease resistant compounds (1996-10-22),

2. 5338475 - Carpet cleaning composition with bleach (1994-08-16),

3. 5308843 - Method of inhibiting mammalian topoisomerase II and malignant cell (1994-05-03),

4. 5288479 - Extrudable elastic oral pharmaceutical gel compositions and metered dose (1994-02-22),

5. 5254592 - Multiply substituted anilines, phenols and pyridines-immunomodulating (1993-10-19),

6. 5245022 - Exonuclease resistant terminally substituted oligonucleotides (1993-09-14),

7. 5223268 - Low solubility drug-coated bead compositions (1993-06-29),

8. 5213811 - Oral sustained-release drug compositions (1993-05-25),

9. 5208336 - Selenomerocyanines and processes for preparation and methods of use and (1993-05-04),

10. 5206231 - 2,5-benzodiazocine antiarrhythmic agents (1993-04-27),

11. 5175178 - 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral (1992-12-29),

12. 5175177 - 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral (1992-12-29),

13. 5172512 - Trap for catching mice and rats (1992-12-22),

14. 5169853 - Pyridinyl-quinolone compounds, their preparation and use (1992-12-08),

15. 5152431 - Pump apparatus for dispensing a selected one of a plurality of liquids (1992-10-06),

Company Overview

Sterling Drug Inc., based in New York, NY, specializes in the development and manufacturing of innovative pharmaceutical compositions. The company focuses on advanced therapeutic areas, including nuclease resistant compounds, oral pharmaceutical gels, and antiviral agents. Sterling Drug is also engaged in creating sustained-release formulations and immunomodulating compounds, alongside drug nanoparticles and anticoagulant compositions. Their research aims to enhance drug efficacy and patient outcomes through cutting-edge technology in the pharmaceutical field.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

692 Patents

#28 in New York, NY

#49 in New York

#728 in US

#1,446 in the World

New York, NY, United States of America

Sterling Drug Inc.

Forward Citations = 9,804

286 inventors:

George Y Lesher (107 out of 108 patents)

Baldev Singh (52 out of 62 patents)

Malcolm R Bell (47 out of 60 patents)

4. Guy D Diana (46 out of 73 patents)

5. Nathan N Crounse (43 out of 49 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sterling Drug Inc.. Retrieved from https://idiyas.com/company/sterling-drug

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…